Triple GIP/GLP-1/Glucagon Agonist • Coming Soon
The Next Frontier in Weight Loss Therapy
Retatrutide is an investigational triple-action receptor agonist targeting GIP, GLP-1, and glucagon pathways simultaneously. Phase 2 trials showed unprecedented results—up to 24.2% body weight reduction. Currently in Phase 3 clinical trials with FDA approval anticipated in 2026. Join our waitlist to be notified when R10 and R50 become available.
24.2%
Avg Body Weight Loss*
48
Week Phase 2 Trial
1x
Weekly Injection
2026
Expected FDA Decision
Coming Soon
Once FDA-approved, we plan to offer two concentrations to support your weight loss journey from titration through maintenance. Join our waitlist to be notified when these become available.
10mg per vial
Ideal For
New patients beginning retatrutide therapy who need lower doses during the titration period.
50mg per vial
Ideal For
Patients who have completed titration and are on therapeutic doses during active weight loss phase.
The Science
Retatrutide (LY3437943) is an investigational triple-action receptor agonist that simultaneously targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This first-in-class approach activates three hormone pathways for potentially superior weight loss.
The addition of glucagon receptor activation is what sets retatrutide apart. While GIP and GLP-1 reduce appetite and improve insulin sensitivity, glucagon increases energy expenditure and fat burning—creating a more comprehensive approach to weight management.
In the Phase 2 trial published in the New England Journal of Medicine, participants on the highest dose achieved an average of 24.2% body weight loss over 48 weeks—the highest ever recorded in obesity medication trials. Phase 3 trials (TRIUMPH program) are currently underway.
Join the Waitlist
How It Works
Retatrutide’s unprecedented approach activates three hormone pathways simultaneously for maximum effect.
Enhances insulin sensitivity and fat metabolism, amplifying the weight loss effects of GLP-1. Works synergistically with the other pathways for improved metabolic outcomes.
Reduces appetite, slows gastric emptying, and promotes prolonged satiety—the proven mechanism behind semaglutide and tirzepatide’s effectiveness.
The differentiator—increases energy expenditure, promotes fat oxidation, and enhances hepatic fat reduction. This third pathway may explain retatrutide’s superior results.
Phase 2 Trial Results
Early clinical data suggests retatrutide may deliver superior weight loss compared to existing FDA-approved options. Results are from Phase 2 trials; Phase 3 data pending.
*Phase 2 results at 48 weeks. Phase 3 trials ongoing. Not yet FDA approved.
Potential Benefits
Phase 2 trials showed 24.2% average body weight loss at the highest dose—surpassing both semaglutide (15%) and tirzepatide (22.5%) in comparable timeframes.
The only investigational agent targeting GIP, GLP-1, and glucagon receptors simultaneously—potentially offering more comprehensive metabolic benefits.
Glucagon receptor activation may increase energy expenditure and promote fat oxidation—a mechanism not present in current GLP-1 or dual-agonist medications.
Phase 2 data showed improvements in blood pressure, triglycerides, LDL cholesterol, HbA1c, and fasting glucose—benefits extending beyond weight loss.
Like existing GLP-1 therapies, retatrutide is administered as a once-weekly subcutaneous injection—simple to incorporate into any routine.
TRIUMPH trials are evaluating retatrutide for NAFLD/NASH, with glucagon’s effects on hepatic fat suggesting potential benefits for fatty liver disease.
What to Do Now
Retatrutide isn’t available yet, but you don’t have to wait to start your weight loss journey. Here’s how we can help today.
Sign up to be notified when retatrutide receives FDA approval and becomes available at BHRC.
Meet with our physicians to discuss FDA-approved options like semaglutide or tirzepatide that are available now.
Begin your weight loss journey with proven therapies while monitoring retatrutide’s progress through trials.
When retatrutide becomes available, discuss with your physician whether switching makes sense for your goals.
Clinical Trial Status
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH program). While early results are promising, it has not yet been approved by the FDA for commercial use.
TRIUMPH
Phase 3 clinical program with multiple trials for obesity and related conditions
2026
Expected completion of Phase 3 trials and potential FDA submission
Questions
No, retatrutide is not yet FDA approved. It is currently in Phase 3 clinical trials (the TRIUMPH program). Based on the trial timeline, FDA approval is expected no earlier than mid-2026. Until then, retatrutide is only available to participants in clinical trials.
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon), while tirzepatide is a dual agonist (GIP + GLP-1) and semaglutide targets only GLP-1. The addition of glucagon receptor activation may increase energy expenditure and fat burning, potentially explaining why Phase 2 trials showed 24.2% weight loss compared to 22.5% for tirzepatide and 15% for semaglutide.
R10 (10mg vial) is designed for the titration phase when patients use lower doses (1–4mg weekly). R50 (50mg vial) is for patients on therapeutic doses (8–12mg weekly) and provides extended supply per vial. These formulations are planned for when retatrutide receives FDA approval.
The most common side effects in Phase 2 trials were gastrointestinal: nausea, diarrhea, vomiting, and constipation—similar to existing GLP-1 therapies. These were generally mild to moderate and occurred mainly during dose escalation. Some participants also reported skin sensitivity, though this was uncommon and did not lead to treatment discontinuation.
Retatrutide is only available through clinical trial participation. Be cautious of any source claiming to sell retatrutide outside of trials—these products are unregulated and potentially dangerous. If you’re interested in weight loss treatment now, we offer FDA-approved options like semaglutide and tirzepatide.
Phase 3 trials are expected to complete by mid-2026. If results are positive and FDA review proceeds normally, commercial availability could follow in late 2026 or 2027. Join our waitlist to be notified as soon as we have updates on availability.
You don’t have to wait to start your weight loss journey. FDA-approved medications like semaglutide (S5, S10, S20) and tirzepatide (T10, T50) are available now at BHRC and have demonstrated significant results. Our physicians can help you start treatment today and discuss transitioning to retatrutide when it becomes available if appropriate.
Stay Updated
Be the first to know when retatrutide becomes available. In the meantime, our team can discuss FDA-approved options like semaglutide and tirzepatide.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*Retatrutide is an investigational medication currently in Phase 3 clinical trials and is NOT FDA approved for commercial sale. The weight loss figures cited (24.2%) are from Phase 2 trials and may differ from final Phase 3 results. Retatrutide is only available through clinical trial participation. Any source claiming to sell retatrutide outside of clinical trials is unregulated and potentially dangerous. BHRC does not currently offer retatrutide. This page is for informational purposes only. Consult with our medical team about FDA-approved weight loss options available today.
